Huanhuan Wang

Huanhuan Wang

Auto-generated profile, based on publicly available information

Huanhuan Wang

Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
HWHuanhuan Wang
Huanhuan Wang
CCCheng Cui
Cheng Cui
HLHaiming Liu
Haiming Liu
BZBo Zhang
Bo Zhang
TTTao Tian
Tao Tian
LGLijian Gao
Lijian Gao
Purpose: Radial artery occlusion (RAO) is an unresolved complication after transradial artery (TRA) puncture. The aim of this observational study was to assess the feasibility and safety of retrograde recanalization of RAO through distal transradial access (dTRA). Methods: From June 2021 to March 2022, 28 consecutive patients with successful puncture and intubation through the dTRA in the anatomical snuffbox and RAO confirmed by angiography were enrolled. Results: Among the 28 patients, 27 (96.4%) patients with RAO were successfully retrogradely recanalized through the dTRA and successfully underwent coronary angiography or coronary intervention. After the procedure, only 1 (3.7%) patient developed a forearm hematoma, and there were no other bleeding complications or nerve disorders. Conclusions: DTRA is a safe and feasible approach for retrograded recanalization of RAO, with a high procedure success rate and few complications.

26 October 2017 in Angiology
Verified
Journal Article
Closed access
HWHuanhuan Wang
Huanhuan Wang
ZGZhan Gao
Zhan Gao
YSYing Song
Ying Song
XTXiaofang Tang
Xiaofang Tang
JXJingjing Xu
Jingjing Xu
JYJinqing Yuan
Jinqing Yuan
Aim: To investigate the impact of diabetic status on 2-year clinical outcomes in Chinese patients undergoing contemporary percutaneous coronary intervention (PCI) treatment. Methods and Results: A total of 10 724 consecutive patients underwent PCI at Fu Wai Hospital were prospectively collected. Two-year clinical outcomes were compared between patients with and without diabetes mellitus (DM). Diabetic patients had more baseline clinical risks and more extensive coronary disease. During 2-year follow-up, the rates of all-cause death, myocardial infarction (MI), revascularization, and major adverse cardiac events (MACE) were significantly higher in DM group. After multivariable-adjusted Cox regression analysis, DM was an independent risk factor for MACE but not for the individual components of MACE. After performing propensity score matching, rates of all-cause death, MI, revascularization, stroke, stent thrombosis, and MACE were not significantly different between the 2 groups, and DM was not predictive of MACE and any clinical adverse outcomes. Conclusions: Diabetic patients who underwent PCI had worse prognosis including death and repeat revascularization during 2-year follow-up, but DM was not an independent risk factor for adverse clinical outcomes.

16 May 2023 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
HWHuanhuan Wang
Huanhuan Wang
DLDan Liu
Dan Liu
JGJidong Guo
Jidong Guo
NHNuerbahati Heisha
Nuerbahati Heisha
LWLei Wang
Lei Wang
LGLijian Gao
Lijian Gao
Background and Aims. The distal transradial access (dTRA) is a new puncture site for coronary catheterization. We sought to evaluate the feasibility, safety, and complication rates of using the dTRA for cardiac catheterization in Chinese patients. Methods. A total of 263 consecutive patients who underwent catheterization through the dTRA were enrolled. The primary endpoint of the study was the rate of conversion to another access site due to the impossibility of successful artery puncture or intubation. Secondary safety endpoints were the rates of bleeding-related complications and nerve disorders. Results. Among 263 patients, the puncture success rate was 96.2 (253/263). Eleven patients were successfully punctured, but the guide wire was difficult to advance. One patient had intubation failure, and the success rate of intubation was 91.6 (241/263). Two hundred thirty-three patients underwent puncture via the right dTRA, 5 patients underwent puncture via the left dTRA, and 3 patients underwent puncture via the bilateral dTRA. A total of 158 (65.6) patients underwent coronary angiography, and 83 (34.4) patients underwent percutaneous coronary intervention. After the procedure, only 2 (0.8) patients had mild bleeding at the puncture site, 2 (0.8) had a forearm hematoma, and no patient had a nerve disorder. Conclusions. DTRA has a low incidence of complications, making it a safe and effective technique for cardiac catheterization.

14 August 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
XTXiao-Fang Tang
Xiao-Fang Tang
YMYuan-Liang Ma
Yuan-Liang Ma
YSYing Song
Ying Song
JXJing-Jing Xu
Jing-Jing Xu
YYYi Yao
Yi Yao
JYJinqing Yuan
Jinqing Yuan
To improve outcomes in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention remain an unmet clinical need. The study aimed to evaluate the efficacy and safety of G2-DESs and BP-DESs in patients with and without DM in a single center in China. A total of 7666 consecutive patients who exclusively had G2-DES or BP-DES implantation throughout 2013 in our center were studied. The primary efficacy endpoint was any target lesion revascularization (TLR), whereas the primary safety endpoint was a composite of death or myocardial infarction (MI) at 2-year follow-up. G2-DESs had a similar occurrence of death, non-fatal MI, TLR, stroke, and stent thrombosis compared with BP-DESs in patients with DM (all P > 0.05). The incidence of TVR and TLR was lower for G2-DESs than for BP-DESs in patients without DM (3.2% vs. 5.1%, P = 0.002; 2.2% vs. 4.5%, P < 0.001, respectively). Kaplan–Meier analysis also showed better TVR- and TLR-free survival rates for G2-DESs than for BP-DESs in patients without DM. Multivariate analysis showed that a BP-DES was an independent risk factor for TLR (hazard ratio 1.963, 95% confidence interval 1.390–2.772, P < 0.001) in patients without DM, which was not predictive of other components of major adverse cardiac events (P > 0.05). G2-DESs have better efficacy, represented by a reduced risk of TLR, and similar safety compared with BP-DESs in patients without DM. G2-DESs have similar efficacy and safety compared with BP-DESs in patients with DM at 2-year follow-up.

3 May 2017 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
HWHuanhuan Wang
Huanhuan Wang
ZGZhan Gao
Zhan Gao
XZXueyan Zhao
Xueyan Zhao
SQShubin Qiao
Shubin Qiao
YYYuejin Yang
Yuejin Yang
JYJinqing Yuan
Jinqing Yuan
Summary: Background: Although numerous studies, to date, have demonstrated a specific phenomenon called the “obesity paradox” in patients after percutaneous coronary intervention (PCI), studies performed in China thus far have consistently shown an absence of this phenomenon.Hypothesis: “Obesity paradox” does exist in Chinese PCI patients.Methods: 10 724 consecutive Chinese patients who had undergone PCI treatment at a single center from January 2013 to December 2013 were prospectively recruited. Patients were divided into four groups: underweight (body mass index [BMI<18.5 kg/m2]), normal weight (18.5 kg/m2≤BMI<24.0 kg/m2), overweight (24.0 kg/m2≤BMI<28.0 kg/m2), and obese (BMI≥28.0 kg/m2). Two‐year clinical outcomes were compared across the groups.Results: Overall, mean (±SD) BMI of all the patients was 25.9±3.2 kg/m2. The 2‐year mortality across underweight, normal weight, overweight, and obese patients in different BMI groups was 2.2%, 1.7%, 1.1%, and 1.0%, respectively (P=.035). Kaplan‐Meier curves revealed that normal weight patients had higher incidence of all‐cause mortality than overweight and obese (P=.015 and P=.020, respectively). Multivariable Cox regression analysis indicated that overweight was an independent predictor of all‐cause mortality compared with normal weight (HR 0.64, 95% CI 0.41‐0.98, P=.042).Conclusions: Overweight patients have lower risk of mortality after PCI treatment; therefore, the phenomenon of “obesity paradox” also seems to exist in Chinese PCI patients.

23 December 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MLMinghao Liu
Minghao Liu
YDYuan Du
Yuan Du
CCCheng Cui
Cheng Cui
JZJinwei Zhai
Jinwei Zhai
WYWei Yu
Wei Yu
LGLijian Gao
Lijian Gao
Background: Transradial access (TRA) is the standard vascular approach for coronary interventions because it lowers bleeding risk and improves patient comfort. Nevertheless, radial artery occlusion (RAO) remains an important limitation, preventing re-use of the radial artery for subsequent procedures. Distal transradial access (dTRA) has been proposed as a strategy to further reduce RAO while preserving procedural efficacy. Aims: To assess whether dTRA reduces early and mid-term RAO compared with conventional TRA in patients undergoing percutaneous coronary intervention (PCI). Methods: In this single-center, prospective, randomized, open-label superiority trial, 426 consecutive patients scheduled for elective PCI between July 2023 and January 2024 were assigned 1:1 to dTRA ( n = 213) or TRA ( n = 213). Duplex ultrasonography was used to assess RAO at 24 h and 30 days. Primary endpoint: 24-hour RAO; secondary endpoints: 30-day RAO, procedural success, hemostasis time, radiation exposure, and hand/wrist function scores. Results: One patient withdrew consent, leaving 425 patients (dTRA 213, TRA 212) for analysis. The 24-hour RAO rate was significantly lower in the dTRA group compared to the TRA group (0.5% vs. 8.7%, p < 0.001). At 30 days, RAO remained lower in the dTRA group (1.6% vs. 8.2%, p < 0.001). Median hemostasis time was 3.0 h with dTRA versus 6.0 h with TRA ( p < 0.001). Procedural success was comparable between groups (82.2% vs. 80.2%; p = 0.72), as was the fluoroscopy dose (1630.0 mGy [1069.0–2481.0] vs. 1598.0 mGy [1039.0–2512.0], p = 0.73). Early wrist function scores were marginally better in the dTRA group ( p = 0.048). Conclusions: In elective PCI patients, dTRA significantly reduces RAO incidence and shortens hemostasis time compared to TRA, without compromising procedural success or increasing radiation exposure, while modestly improving early hand function. These data support routine adoption of dTRA for coronary interventions. Trial registration: Chinese Clinical Trial Registry: ChiCTR2300073902 (registered on 25 July 2023).